BL

Bliss GVS Pharma LtdNSE BLISSGVS Stock Report

Last reporting period 31 Mar, 2024

Updated 08 Nov, 2024

Last price

Market cap $B

0.234

Micro

Exchange

XNSE - National Stock Exchange Of India

BLISSGVS.NS Stock Analysis

BL

Uncovered

Bliss GVS Pharma Ltd is uncovered by Eyestock quantitative analysis.

Market cap $B

0.234

Dividend yield

0.44 %

Shares outstanding

104.69 B

Bliss GVS Pharma Ltd. engages in the development, manufacture, and marketing of pharmaceutical formulations. The company is headquartered in Mumbai, Maharashtra and currently employs 763 full-time employees. The company went IPO on 2010-07-26. The Company’s product categories include pharma products and other healthcare products. Its pharma products include pharma products include capsules, creams, gels, ointments, dry powder for injection, effervescent tablets, eye/ear drops, nasal solution, lotions, lozenges, soft gelatine capsules and syrups. The Company’s other healthcare products include balm, nasal inhaler, solution, soap, vaginal wash, roll on, shampoo, powder, spray, and petroleum jelly. Its brands include ANOMEX, ANOMEX DS, CONLAX 5/10, G - ALFENAC 100, GACET 80/125/170/250/500/1G, GMETH - 50/100, GSUNATE - 50/100/200, GVCAM - 7.5/15, GV-SOFT 1/2/3/4 G, LOFNAC - 12.5/25/50/100, MEFINOL, MELANEZ, MENINA - 25/100, TYRIDOL, VIGOTAMIN, COMIT 50, BG - CLIND, VAGID CL, ECOZOLE, GVGYL 500, GYNANFORT, GVGYL N, KLOVINAL, LONART, LONART FORTE, LONART Dispersible, FINMOL, GACET-500, and DOXYCYCLINE.

View Section: Eyestock Rating